Eledon Pharmaceuticals (ELDN) News Today $3.01 +0.03 (+1.01%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$3.09 +0.08 (+2.62%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Is Eledon Pharmaceuticals (ELDN) The Hot Biotech Stock Under $5?March 27, 2025 | uk.finance.yahoo.comCantor Fitzgerald Weighs in on ELDN FY2025 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Cantor Fitzgerald dropped their FY2025 earnings estimates for Eledon Pharmaceuticals in a research note issued to investors on Monday, March 24th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the compaMarch 27, 2025 | marketbeat.comLeerink Partnrs Has Negative Outlook of ELDN FY2025 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a research report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith now anticipates that the compaMarch 27, 2025 | marketbeat.comEquities Analysts Set Expectations for ELDN Q1 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a report issued on Sunday, March 23rd. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.28) perMarch 26, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Biomea Fusion (BMEA), Eledon Pharmaceuticals (ELDN)March 24, 2025 | markets.businessinsider.comGuggenheim Remains a Buy on Eledon Pharmaceuticals (ELDN)March 24, 2025 | markets.businessinsider.comWe're Hopeful That Eledon Pharmaceuticals (NASDAQ:ELDN) Will Use Its Cash WiselyMarch 22, 2025 | finance.yahoo.comEledon Pharmaceuticals Reports 2024 Financial Results and Clinical AdvancesMarch 22, 2025 | tipranks.comEledon Pharmaceuticals (NASDAQ:ELDN) Posts Earnings Results, Misses Estimates By $0.30 EPSEledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) announced its earnings results on Thursday. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.30).March 21, 2025 | marketbeat.comEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial ResultsMarch 20, 2025 | globenewswire.comEledon Pharmaceuticals (ELDN) to Release Earnings on ThursdayEledon Pharmaceuticals (NASDAQ:ELDN) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comEledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 3.4% - Here's WhyEledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 3.4% - Should You Sell?March 5, 2025 | marketbeat.comEledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare ConferenceMarch 4, 2025 | globenewswire.comLeerink Partnrs Has Pessimistic View of ELDN Q4 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Leerink Partnrs reduced their Q4 2024 earnings estimates for shares of Eledon Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($0.32) per shFebruary 10, 2025 | marketbeat.comEledon Pharmaceuticals' Investigational Therapy Tegoprubart Successfully Used in Landmark Kidney Xenotransplant at Mass General Transplant CenterFebruary 9, 2025 | nasdaq.comEledon's tegoprubart used in second pig-to-human kidney transplantFebruary 7, 2025 | msn.comEledon announces tegoprubart use in transplant of pig kidney into humanFebruary 7, 2025 | markets.businessinsider.comEledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a HumanFebruary 7, 2025 | globenewswire.comFY2029 Earnings Estimate for ELDN Issued By Leerink PartnrsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a report released on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the companyFebruary 7, 2025 | marketbeat.comEledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech ConferenceJanuary 29, 2025 | globenewswire.comEledon Pharmaceuticals initiated with a Buy at GuggenheimJanuary 28, 2025 | markets.businessinsider.comEledon initiated with a Buy at Guggenheim on tegoprubart opportunityJanuary 28, 2025 | markets.businessinsider.comEledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management BusinessJanuary 28, 2025 | seekingalpha.comEledon Pharmaceuticals (NASDAQ:ELDN) Coverage Initiated by Analysts at GuggenheimGuggenheim initiated coverage on shares of Eledon Pharmaceuticals in a research note on Tuesday. They set a "buy" rating and a $9.00 target price for the company.January 28, 2025 | marketbeat.comInspire Investing LLC Invests $802,000 in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Inspire Investing LLC acquired a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 194,688 shares of the company's stock, valued at approximately $802,000.January 25, 2025 | marketbeat.comBrokers Set Expectations for ELDN FY2025 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Eledon Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnJanuary 22, 2025 | marketbeat.comEledon Pharmaceuticals (ELDN) Receives a Rating Update from a Top AnalystJanuary 16, 2025 | markets.businessinsider.comEledon Pharmaceuticals highlights recent business milestones, 2025 outlookJanuary 13, 2025 | msn.comEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 OutlookJanuary 13, 2025 | globenewswire.comEledon Pharmaceuticals (NASDAQ:ELDN) Stock Price Down 3.9% - Time to Sell?Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 3.9% - Time to Sell?January 7, 2025 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest UpdateEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 686,700 shares, a drop of 6.1% from the November 15th total of 731,500 shares. Based on an average trading volume of 432,200 shares, the days-to-cover ratio is currently 1.6 days.December 16, 2024 | marketbeat.comQ4 EPS Forecast for Eledon Pharmaceuticals Cut by AnalystEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Stock analysts at HC Wainwright dropped their Q4 2024 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a research note issued on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now expects that theNovember 22, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Eledon Pharmaceuticals (NASDAQ:ELDN)HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Eledon Pharmaceuticals in a research note on Wednesday.November 20, 2024 | marketbeat.comResearch Analysts Set Expectations for ELDN FY2024 EarningsEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2024 earnings per share estimates for Eledon Pharmaceuticals in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the compaNovember 18, 2024 | marketbeat.comEledon Pharmaceuticals: Strong Financials and Promising Clinical Developments Justify Buy RatingNovember 15, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for ELDN Issued By Lifesci CapitalEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Analysts at Lifesci Capital lifted their FY2024 EPS estimates for shares of Eledon Pharmaceuticals in a report released on Wednesday, November 13th. Lifesci Capital analyst R. Katkhuda now expects that the company will post earnings per sNovember 15, 2024 | marketbeat.comEledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutionsNovember 14, 2024 | finance.yahoo.comEledon Pharmaceuticals Reports Strong Q3 2024 ResultsNovember 14, 2024 | markets.businessinsider.comEledon Pharmaceuticals price target lowered to $20.50 from $28 at LadenburgNovember 14, 2024 | markets.businessinsider.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deEledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comEledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation ConferenceNovember 6, 2024 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Make Eledon Pharmaceuticals a Compelling InvestmentOctober 30, 2024 | markets.businessinsider.comNoble Financial Reaffirms Their Buy Rating on Eledon Pharmaceuticals (ELDN)October 30, 2024 | markets.businessinsider.comBuy Rating Justified for Eledon Pharmaceuticals Amid Promising Clinical Developments and Financial StabilityOctober 29, 2024 | markets.businessinsider.comEledon Pharmaceuticals prices 18.36M shares at $3.65 in underwritten offeringOctober 29, 2024 | markets.businessinsider.comEledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial DataOctober 29, 2024 | marketwatch.comEledon: Changing Scope Of Immunosuppressive Drug Space With TegoprubartOctober 29, 2024 | seekingalpha.comEledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsOctober 29, 2024 | globenewswire.comEledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago MedicineOctober 29, 2024 | globenewswire.com Remove Ads Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address ELDN Media Mentions By Week ELDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELDN News Sentiment▼1.890.79▲Average Medical News Sentiment ELDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELDN Articles This Week▼11▲ELDN Articles Average Week Remove Ads Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NUVB News Today CRON News Today PHVS News Today EOLS News Today XERS News Today LENZ News Today IMNM News Today RCKT News Today XNCR News Today ABUS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELDN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ELDN Stock Free ELDN Stock Alerts